TAO Synergies Inc./$TAOX
1D1W1MYTD1Y5YMAX
About TAO Synergies Inc.
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
- Ticker
- $TAOX
- Sector
- Software & Cloud Services
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- New York, United States
- Website
- taosynergies.com
TAOX Metrics
BasicAdvanced
$32M
-
-$3.39
1.47
-
Price and volume
Market cap
$32M
Beta
1.47
52-week high
$10.00
52-week low
$3.07
Average daily volume
115K
Financial strength
Current ratio
19.985
Quick ratio
2.296
Profitability
EBITDA (TTM)
-8.526
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,155.49%
Operating margin (TTM)
-1,104.08%
Management effectiveness
Return on assets (TTM)
-26.07%
Return on equity (TTM)
-94.45%
Valuation
Price to revenue (TTM)
34.892
Price to book
2.51
Price to tangible book (TTM)
2.51
Price to free cash flow (TTM)
-3.946
Free cash flow yield (TTM)
-25.34%
Free cash flow per share (TTM)
-1.085
Growth
Revenue change (TTM)
19,397.70%
Earnings per share change (TTM)
-83.57%
3-year earnings per share growth (CAGR)
-55.22%
TAOX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.